Type 1 Diabetes TrialNet (coming soon!)
EXenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A randomized, placebo-controlled clinical trial to evaluate cardiovascular outcomes after treatment with Exenatide once weekly in patients with Type 2 diabetes mellitus. Phase 3b/4. Sponsors: Amylin Pharmaceuticals, Inc. and Eli Lilly and Co.
For more information about these studies, please contact Teri Lavenbarg, APRN, FNP-BC, PNP,-BC, CDE.